| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $650,621 | 8 | 100 |
Sells | $0 | 0 | 0 |
| Vaddi Krishna | CEO | 7 | $581,371 | 0 | $0 | $581,371 |
| Combs Andrew | Chief Chemistry Officer | 1 | $69,250 | 0 | $0 | $69,250 |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Over the last 12 months, insiders at Prelude Therapeutics Incorporated have bought $650,621 and sold $0 worth of Prelude Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Prelude Therapeutics Incorporated have bought $2.26M and sold $5.2M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Vaddi Krishna (CEO) — $581,371. Combs Andrew (Chief Chemistry Officer) — $69,250.
The last purchase of 675,000 shares for transaction amount of $467,438 was made by Vaddi Krishna (CEO) on 2025‑03‑25.
| 2025-03-25 | Vaddi Krishna | CEO | 675,000 1.2187% | $0.69 | $467,438 | +62.50% | ||
| 2025-03-25 | Combs Andrew | Chief Chemistry Officer | 100,000 0.1806% | $0.69 | $69,250 | +62.50% | ||
| 2025-03-21 | Vaddi Krishna | CEO | 15,000 0.028% | $0.73 | $10,959 | +59.02% | ||
| 2025-03-20 | Vaddi Krishna | CEO | 5,416 0.0097% | $0.73 | $3,950 | +52.07% | ||
| 2025-03-17 | Vaddi Krishna | CEO | 9,106 0.0164% | $0.75 | $6,829 | +45.71% | ||
| 2025-03-14 | Vaddi Krishna | CEO | 29,999 0.0447% | $0.75 | $22,631 | +47.69% | ||
| 2025-03-13 | Vaddi Krishna | CEO | 50,000 0.0921% | $0.72 | $35,820 | +55.61% | ||
| 2025-03-12 | Vaddi Krishna | CEO | 47,500 0.0881% | $0.71 | $33,744 | +56.56% | ||
| 2024-12-31 | Vaddi Krishna | CEO | 5,000 0.0087% | $1.21 | $6,044 | -21.86% | ||
| 2024-12-30 | Vaddi Krishna | CEO | 10,000 0.0163% | $1.20 | $12,000 | -17.99% | ||
| 2024-12-23 | Combs Andrew | Chief Chemistry Officer | 60,000 0.1202% | $1.37 | $82,002 | -19.97% | ||
| 2024-12-20 | Combs Andrew | Chief Chemistry Officer | 3,075 0.0055% | $1.15 | $3,536 | -24.25% | ||
| 2024-12-19 | Vaddi Krishna | CEO | 6,888 0.0122% | $0.89 | $6,116 | +11.75% | ||
| 2024-12-19 | Lim Bryant David | CLO, Interim CFO, Corp Sec. | 25,000 0.0452% | $0.91 | $22,638 | +11.75% | ||
| 2024-12-18 | Vaddi Krishna | CEO | 100,000 0.1882% | $0.93 | $93,210 | +8.51% | ||
| 2023-05-25 | Vaddi Krishna | CEO | 900 0.0019% | $5.31 | $4,779 | -28.14% | ||
| 2023-05-24 | Vaddi Krishna | CEO | 1,000 0.002% | $5.01 | $5,011 | -26.55% | ||
| 2023-05-24 | Lim Bryant David | Chief Legal Officer, Corp Sec. | 2,400 0.0053% | $5.39 | $12,936 | -26.55% | ||
| 2023-05-23 | Vaddi Krishna | CEO | 11,856 0.0257% | $5.63 | $66,749 | -30.46% | ||
| 2023-05-23 | Chardonnet Laurent | Chief Financial Officer | 5,000 0.0106% | $5.50 | $27,500 | -30.46% |
| Vaddi Krishna | CEO | 1999296 3.6229% | $4.34M | 15 | 0 | <0.0001% |
| Combs Andrew | Chief Chemistry Officer | 480123 0.87% | $1.04M | 6 | 0 | <0.0001% |
| ORBIMED ADVISORS LLC | 10119756 18.3381% | $21.96M | 5 | 0 | <0.0001% | |
| Bonita David P | 10119756 18.3381% | $21.96M | 5 | 0 | +8.96% | |
| BAKER BROS. ADVISORS LP | 5212371 9.4454% | $11.31M | 4 | 0 | +34.76% | |
| Scherle Peggy | Chief Scientific Officer | 172920 0.3133% | $375,236.40 | 0 | 7 | |
| FRIEDMAN PAUL A | director | 152576 0.2765% | $331,089.92 | 1 | 0 | |
| Chardonnet Laurent | Chief Financial Officer | 42165 0.0764% | $91,498.05 | 3 | 0 | +5.29% |
| Lim Bryant David | CLO, Interim CFO, Corp Sec. | 27400 0.0497% | $59,458.00 | 2 | 0 | <0.0001% |
| Huang Jane | President, CMO | 24220 0.0439% | $52,557.40 | 0 | 1 | |
| Dier Mardi | director | 10000 0.0181% | $21,700.00 | 1 | 0 | +34.76% |
| Pierce Christopher | EVP and Chief of Business Oper | 3750 0.0068% | $8,137.50 | 1 | 4 | +34.76% |
| Morosini Deborah | EVP, Chief of Clinical Affairs | 444 0.0008% | $963.48 | 1 | 5 | +34.76% |
| Mauro David J | Chief Medical Officer | 0 0% | $0 | 0 | 10 | |
| Piper Brian | Chief Financial Officer | 0 0% | $0 | 0 | 2 |
$5,262,089 | 154 | 5.62% | $98.8M | |
$17,525,882 | 60 | 5.22% | $101.49M | |
$18,994,888 | 46 | 88.59% | $107.78M | |
$6,861,925 | 44 | 8.31% | $120.13M | |
$140,595,157 | 34 | 17.93% | $99.98M | |
Prelude Therapeutics Incorporated (PRLD) | $167,701,902 | 27 | -3.07% | $119.75M |
$47,292,212 | 27 | -28.21% | $134.01M | |
$295,092,700 | 21 | -0.27% | $131.5M | |
$38,821,584 | 20 | -2.17% | $114.5M | |
$178,593,887 | 15 | -14.86% | $128.48M | |
$156,530,514 | 13 | 45.71% | $111.15M | |
$15,799,576 | 12 | -39.52% | $131.29M | |
$9,999,920 | 10 | -40.03% | $118.38M | |
$2,762,881 | 8 | -10.76% | $120.71M | |
$5,524,590 | 7 | 7.40% | $113.94M | |
$68,692,148 | 6 | -39.10% | $100.69M | |
$20,729,984 | 5 | 51.71% | $132.22M | |
$556,839 | 5 | 13.42% | $129.54M | |
$19,175,155 | 2 | 40.00% | $126.29M |
| Increased Positions | 14 | +20.29% | 1M | +4.27% |
| Decreased Positions | 29 | -42.03% | 964,681 | -2.94% |
| New Positions | 6 | New | 44,929 | New |
| Sold Out Positions | 7 | Sold Out | 456,138 | Sold Out |
| Total Postitions | 54 | -21.74% | 33M | +1.33% |
| Orbimed Advisors Llc | $45,289.00 | 37.7% | 16.59M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $27,638.00 | 23.01% | 10.12M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $3,131.00 | 2.61% | 1.15M | +898,621 | +361.73% | 2025-09-30 |
| Vanguard Group Inc | $2,710.00 | 2.26% | 992,854 | +60,284 | +6.46% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $2,392.00 | 1.99% | 876,338 | -51,270 | -5.53% | 2025-09-30 |
| Renaissance Technologies Llc | $1,485.00 | 1.24% | 544,000 | -37,800 | -6.5% | 2025-09-30 |
| Acadian Asset Management Llc | $1,476.00 | 1.23% | 540,565 | 0 | 0% | 2025-09-30 |
| Morgan Stanley | $776.00 | 0.65% | 284,203 | -179 | -0.06% | 2025-09-30 |
| Blackrock, Inc. | $723.00 | 0.6% | 264,973 | -167,586 | -38.74% | 2025-09-30 |
| Two Sigma Advisers, Lp | $608.00 | 0.51% | 222,700 | -2,300 | -1.02% | 2025-09-30 |